Placebo-controlled multicentre randomised trial of interferon beta-1b in treatment of secondary progressive multiple sclerosis

Auszug aus der Publikation der European Study Group on Interferon beta-1b in SPMS, 1998¹

Background

The beneficial effects of interferon have only been shown for patients in the relapsing-remitting phase of multiple sclerosis (MS).

Studienziel

• Wirksamkeit, Sicherheit und Verträglichkeit von Betaferon bei Patienten mit sekundär-progredienter MS

Primäre Endpunkte

• Zeit bis zur bestätigten Behinderungsprogression

Interferon beta-1b in treatment-naive paediatric patients with relapsing-remitting multiple sclerosis: Two-year results from the BETAPAEDIC study.

Auszug aus der Publikation von Gärtner et al., 2017

Background and objective

Study evaluating Betaferon's safety and tolerability in paediatric patients with multiple sclerosis (BETAPAEDIC) is a prospective, open-label observational multicentre study to assess the safety and effectiveness of interferon beta-1b in paediatric patients with

Schlussfolgerung

Interferon beta-1b scheint eine wirksame Behandlung mit einem günstigen Sicherheitsprofil für pädiatrische Patienten im Alter von 12 bis 16 Jahren zu sein.

Survival in MS: a randomized cohort study 21 years after the start of the pivotal IFN beta-1b trial

Auszug aus der Publikation Goodin DS et al., 2012¹

Abstract

Objective

To examine the effects of interferon beta (IFNβ)-1b on all-cause mortality over 21 years in the cohort of 372 patients who participated in the pivotal randomized clinical trial (RCT), retaining (in the analysis) the original randomized treatment-assignments.

Primärer Endpunkt

• Mortalität

Studienergebnisse

250 μg or 500 μg interferon beta-1b versus 20 mg glatiramer acetate in relapsing-remitting multiple sclerosis: a prospective, randomised, multicentre study

Auszug aus der Publikation von O‘Connor P et al., 2009¹

Summary

Background

The aim of the Betaferon Efficacy Yielding Outcomes of a New Dose (BEYOND) trial was to compare the efficacy, safety, and tolerability of 250 μg or 500 μg interferon beta-1b with glatiramer acetate for treating relapsing-remitting multiple sclerosis.

 Comparison of injection site pain and injection site reactions in relapsing-remitting multiple sclerosis patients treated with interferon beta-1a or 1b

Auszug aus der Publikation von Baum K et al., 2007;13:1153–1160¹

This prospective, multicentre, international, observational, cohort study compared injection site pain (ISP) and injection site reactions (ISRS) between interferon beta-1b (IFNβ-1b; Betaferon) 250 μg subcutaneously every other day and interferon beta-1a (IFNβ-1a; Rebif^®) 44 μg subcutan

Cross-sectional study assessing long-term safety of interferon-beta-1b for relapsing remitting MS

Auszug aus der Publikation von Reder AT et al., 2010¹

Abstract 

Objective

The 16-Year Long-Term Follow-Up (LTF) to the pivotal interferon-β-1b (IFNb-1b) trial explored clinical, MRI, cognitive, and patient-reported outcomes. Here, we report the safety assessments.

Every-other-day interferon beta-1b versus once-weekly interferon beta-1a for multiple sclerosis: results of a 2-year prospective randomised multicentre study (INCOMIN)

Vergleichsstudie

Summary

Background

The three interferon beta preparations approved for treatment of relapsing-remitting multiple sclerosis (MS) differ in dose and frequency of administration.